Apellis Pharmaceuticals (APLS) PT Raised to $60 at Wedbush
Tweet
Share
E-mailGet Alerts APLS Hot Sheet
Price: $41.03 --0%
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
Wedbush analyst Laura Chico raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $60.00 (from $39.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Bernstein SocGen Group Upgrades Analog Devices (ADI) to Outperform
- Avita Medical Ltd. (RCEL) PT Raised to $14 at TD Cowen
- Keysight Technologies (KEYS) PT Raised to $440 at UBS Amid Broad-Based AI Strength
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
